FEC filings through Oct 14, 2026 · FEC bulk filing data · committee C00033969 · files monthly
SummaryAt a glance
Why it exists
No statement of purpose found on its site.
Money
$560K raised, $589.8K spent, $94.3K cash on hand (through Oct 14, 2026). Where it comes from
Who funds it
77% from donors giving over $200 · 21% from donors giving $200 or less · largest donor Victor Bulto Carulla, $10K. See who funds it
Where it goes
$516.5K given to candidates and committees, the largest to Common Ground PAC ($10K) · 43% of its support to Democrats, 43% to Republicans. See where it goes
This committee’s site publishes no list of positions we could read, and we found no statement of why it exists. We do not write one for it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$322.5K to 111 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $322,500
Democratic 43%
Republican 43%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Democratic
39
$139,500
$0
$139,500
43%
Republican
55
$139,000
$0
$139,000
43%
Other or unresolved
17
$44,000
$0
$44,000
14%
Shown support
111
$322,500
$0
$322,500
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$516,500 in 313 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
48
$155K · 30%
Republican candidates
66
$154.5K · 29%
Other or unresolved candidates
18
$45K · 8.6%
Democratic party committees
2
$7.5K · 1.4%
Other PACs and committees
42
$162K · 31%
All recipients
176
$524K
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
North Carolina
11
$45K
California
13
$37.5K
Florida
9
$19.5K
Massachusetts
5
$19K
Indiana
8
$18.5K
New Jersey
6
$17.5K
Virginia
5
$15K
Pennsylvania
4
$14.5K
The largest 8 of 40 states.
Recipients 176
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
S. Brett Brett Guthrie3 receipts, latest Mar 25, 2026Guthrie for Congress · H8KY02031$10K
John Joyce4 receipts, latest May 5, 2026DR John Joyce for Congress · H8PA13125$10K
Don Davis3 receipts, latest Mar 25, 2026Don Davis for NC · H2NC02287$10K
Scott Peters3 receipts, latest Feb 25, 2026Scott Peters for Congress · H2CA52089$9K
Richard L. Hudson Jr.2 receipts, latest May 5, 2026Hudson for Congress · H2NC08185$8.5K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
No committee-to-committee receipts were itemized this cycle.
Committees this one funds
Disbursements this committee itemized to another committee: candidate contributions, party transfers and payments alike, not contributions only.
DR John Joyce for CongressHouse campaign committee · Connected to TEAM JOYCE FOR PENNSYLVANIA · 4 payments
$10K
Guthrie for CongressHouse campaign committee · Connected to LANGWORTHY LEADERSHIP & ACCOUNTABILITY FUND · 3 payments
$10K
Don Davis for NCHouse campaign committee · Connected to BLUE TO THE FUTURE 2024 · 3 payments
Money inWho funds the PAC?
Where the money came from $559,997 reported receipts
Itemized (over $200)Donors who have given more than $200 this cycle, so the FEC itemizes (names) them.$429,50177%
Largest donors
Victor Bulto Carulla2 contributions, latest Mar 20, 2026 · PRESIDENT US · US NOVARTIS PHARMACEUTICALS · EAST HANOVER, NJ$10,000
Katie Mazuk2 contributions, latest Mar 20, 2026 · CHIEF PATIENT EXPERIENCE OFFICER · US NOVARTIS PHARMACEUTICALS · NEW YORK, NY$10,000
Gail Horwood39 contributions, latest Aug 31, 2026 · CHIEF MKT & CUSTOMER EXP OFFICER, US · NOVARTIS · EAST HANOVER, NJ$7,872
Reshema R. Kemps-Polanco39 contributions, latest Aug 31, 2026 · EVP, CHIEF COMMERCIAL OFFICER, US · NOVARTIS · EAST HANOVER, NJ$7,872
Courtney Piron39 contributions, latest Aug 31, 2026 · HEAD, US PUBLIC AFFAIRS · NOVARTIS · EAST HANOVER, NJ$7,872
Vicki A. Rawlinson39 contributions, latest Aug 31, 2026 · HEAD OF EXECUTIVE COACHING · NOVARTIS · EAST HANOVER, NJ$7,872
Michelle Weese39 contributions, latest Aug 31, 2026 · CHIEF CORPORATE AFFAIRS OFFICER · NOVARTIS · EAST HANOVER, NJ$7,872
Eden Wells38 contributions, latest Jul 31, 2026 · EXECUTIVE · NOVARTIS · EAST HANOVER, NJ$7,296
Desmond Creary32 contributions, latest Aug 31, 2026 · CHIEF CUSTOMER ENGAGEMENT OFFICER, US · NOVARTIS · EAST HANOVER, NJ$6,528
Daniel P. Casserly29 contributions, latest Aug 31, 2026 · GLOBAL HEAD PUBLIC AFFAIRS · NOVARTIS · EAST HANOVER, NJ$5,760
Emily Gibb39 contributions, latest Aug 31, 2026 · VP, NPS CVM · NOVARTIS · EAST HANOVER, NJ$5,535
Joseph McGowan39 contributions, latest Aug 31, 2026 · HEAD, FEDERAL GOVERNMENT AFFAIRS · NOVARTIS · EAST HANOVER, NJ$5,535
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 4,145 itemized contributions were filed this cycle, totaling $399.7K. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$119,99621%
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$10,5001.9%
Total reported receipts $559,997
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. Open a source marked + to see who gave. FEC filings through Oct 14, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $399,752 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $14K
$14K+
$56K+
$126.1K+
$224.2K+
none
Top states
Top donor states
Name
Amount
New Jersey3,787 contributions · 88%
$350,242
New York211 contributions · 7.9%
$31,529
District of Columbia98 contributions · 2.2%
$8,969
Massachusetts1 contribution · 1.3%
$5,000
Delaware31 contributions · 0.8%
$3,100
Texas16 contributions · 0.2%
$912
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
SpendingWhere does the money go?
How the spending splits $589,847 reported
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$527,00089%
Paid to
Common Ground PAC3 payments · latest May 27, 2026 · CONTRIBUTION$10,000
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $517,486 itemized
Given to othersContributions to other candidates, party committees, and PACs.$516,50099.8%
Filed as
CONTRIBUTION$516,500
Paid to
Common Ground PAC$10,000
Heartland Values PAC$10,000
DR. John Joyce for Congress$10,000
Guthrie for Congress$10,000
Don Davis for NC$10,000
Juntos PAC$9,000
OtherPayments whose filed description does not match any category above. Every one is listed so it can be read directly.$8400.2%
Filed as
BANK SERVICE CHARGE$684
ANALYSIS SERVICE CHARGE$156
Paid to
Capital One Bank$840
Card paymentsPaid to a card processor with no itemisation filed beneath it, so the purchases behind it are not on the record.$145<0.1%
Filed as
Spending over time
$593.2K spent from Jan 2025 to Oct 2026. Most in one report: $96.6K, March 2026.
$593.2K
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Besides giving through its PAC, Novartis pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$6.2M
Quarterly reports read
36
Bills it named
41
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Health Issuesin 30 report entries · 19 bills named
In its own words
Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program H.R.9504: Tax Exempt Hospital Transparency Act 340B Program Implementation & Oversight H.R. 9599 - SECURE 340B Act Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation (MFN) policy Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Utilization management policies Clinical trial data in China S.3788: CLEAR Labels Act S. 4784/H.R. 8800: National Defense Authorization Act for Fiscal Year 2027
Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation (MFN) policy Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Utilization management policies
Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program H.R.9504: Tax Exempt Hospital Transparency Act 340B Program Implementation & Oversight H.R. 9599 - SECURE 340B Act S. 5244 - SUSTAIN 340B Act Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies Most Favored Nation (MFN) policy Clinical trial data in China S.3788: CLEAR Labels Act S. 4784/H.R. 8800: National Defense Authorization Act for Fiscal Year 2027
Direct to Consumer Advertising. 340B Drug Discount Program - Program Implementation & Oversight.
Accelerated Approval.
Breast Cancer Research.
Supply Chain Integrity and Traceability.
PBM Reform.
Coverage of Accelerated Approval Products.
Drug Benefit Design.
Orphan Drug Issues.
S. 1682/H.R.946: ORPHAN Cures Act.
Reimbursement and Coverage of Innovative Products.
Lower Costs, More Transparency Act.
Lower Costs, More Cures Act.
Patient Cost-Sharing.
Step Therapy.
Value-based Contracting and Communications.
User fee policy issues.
Pharmacy Benefit Manager reform and policy issues.
Drug cost and pricing policy issues.
Drug importation policy issues.
Competition policy issues.
Drug shortages policy issues.
IRA price negotiation expansion policy issues.
Rare Pediatric Disease Priority Review Voucher program policies.
SUSTAIN RFI/discussion draft.
Most Favored Nation (MFN) policy.
Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients.
Utilization management policies.
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy Tribal health issues
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Trade (domestic/foreign)in 24 report entries · 2 bills named
In its own words
Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues Outbound Investment Security Program H.R. 9102/S. 5316 - Biotech Investment National Security Act
Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues Outbound Investment Security Program H.R. 9102 - Biotech Investment National Security Act
Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues
Medicare/Medicaidin 21 report entries · 8 bills named
In its own words
GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues
GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act
Taxation/Internal Revenue Codein 12 report entries · 2 bills named
In its own words
Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms Foreign Direct Investment Expensing of R&D Expenditures H.R. 2425 - Unfair Tax Prevention Act of 2025 Tax Cuts and Jobs Act, PL 115-97 H.R. 1: One Big Beautiful Bill Act (P.L. 119-21)
Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms American Innovation and Jobs Act Foreign Direct Investment Expensing of R&D Expenditures Tax Cuts and Jobs Act, PL 115-97 H.R. 1: One Big Beautiful Bill Act (P.L. 119-21)
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to US and international tax provisions; issues related to ESRD
Budget/Appropriationsin 9 report entries · 4 bills named
In its own words
H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2026 FY 2026 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 Federal Budget Funding for National Institutes of Health - FY 2026 Appropriations H.R. 1: One Big Beautiful Bill Act (P.L. 119-21) FY 2027 President's Budget H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75)
H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 Funding for FDA - FY 2026 Appropriations Federal Budget H.R. 1: One Big Beautiful Bill Act (P.L. 119-21) FY 2027 President's Budget H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103)
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
B Hall Strategies, LLCLobbying firm · 3 reports$90K
Contributions on the LD-203 report
Reported twice a year by the lobbying filer. $282.5K is political giving that also appears in FEC filings.
NRSC$44.3K
susan collins$25K
ashley hinson$8K
Tim Sheehy$6K
Andy Harris$5K
Bill Cassidy$5K
john barrasso$5K
John Barrasso$5K
mike crapo$5K
Rep. Andy Harris$5K
Matched by name: these reports are filed for “NOVARTIS”, found by searching “NOVARTIS”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Oct 26, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Novartis Corp. PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Novartis Corp. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Pages quoted 0 pages
No pages quoted
Nothing from this committee’s or its sponsor’s site is quoted yet.
Linked public records
No approved organization identity yet
The official FEC committee record remains available under Filings.
SPScott H. PetersDemocratic · U.S. House · CA-50 · via Scott Peters For Congress3 payments, latest Feb 25, 2026 · CONTRIBUTION · FEC filing, Feb 25, 2026$9K
RHRichard HudsonRepublican · U.S. House · NC-09 · via Hudson For Congress2 payments, latest May 5, 2026 · CONTRIBUTION · FEC filing, May 5, 2026$8.5K
$524K across 163 recipient committees, or 89% of everything this committee reports spending. The largest 12 are shown.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
Donors’ employers
Employer as filed
Amount
US Novartis Pharmaceuticals2,512 contributions · 54% of ranked
$214,316
US Novartis Services INC1,046 contributions · 27% of ranked
$107,008
Novartis259 contributions · 13% of ranked
$51,499
Novartis Pharmaceuticals25 contributions · 2% of ranked
$7,990
Corporate41 contributions · 1.2% of ranked
$4,719
Commercial Ops-prim Care Andspec50 contributions · 1.2% of ranked
$4,644
US Nibri114 contributions · 1.1% of ranked
$4,537
Novartis Services Incorporated63 contributions · 1% of ranked
$4,108
Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($119,996) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
Occupation as filed
Amount
AD State Government Affairs192 contributions · 2.6% of ranked
EVP Chief Commercial Officer US39 contributions · 2.1% of ranked
$7,872
Global Head Public Affairs39 contributions · 2.1% of ranked
$7,872
US Country Head Of People & Organizati37 contributions · 1.9% of ranked
$7,104
Chief Corporate Affairs Officer34 contributions · 1.8% of ranked
$6,912
Chief Customer Engagement Officer US32 contributions · 1.7% of ranked
$6,528
VP Special Projects10 contributions · 1.7% of ranked
$6,305
Ranked from the largest 200 of 201 occupation spellings filed; each share is of the money in those. Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($119,996) are not itemized, so no employer or occupation is filed for them.
CREDIT CARD PROCESSING FEE$145
Paid to
Paypal Inc.$145
Taxes, fees, and bank chargesPayroll and income taxes, filing fees, bank and merchant processing charges.$1<0.1%
Filed as
MERCHANT FEE$1
Paid to
Paypal Inc.$1
Total itemized disbursements $517,486
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 327 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
↗
Issues related to ongoing trade negotiations;
Issues related to US/China relations;
Issues related to international intellectual property;
Issues related to global health; issues related to supply chain; and issues related to tariffs, issues related to ESRD.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).
GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues
Medicare Part B. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model.
Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule.
Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule.
Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues.
H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025.
Part D redesign and policy issues including non-interference and rebates policy issues.
Part B policy issues.
Drug cost and pricing policy issues.
Medicare rebate policy issues.
CMS IPAY Guidance on the Medicare Drug Price Negotiation Program.
Medicaid rebate policy issues.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169);
Issues related to drug pricing;
Issues related to the One Big Beautiful Bill Act (PL 119-21);
Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program;
Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Provide strategic counsel and advocacy for issues related to policies impacting the pharmaceutical industry generally including drug shortages, patientout of pocket costs, supply chain, PBM policies, kidney care policies, Inflation Reduction Act (IRA) implementation issues, the Maintaining Investments in New Innovation (MINI) Act H.R.1672, tariffs, biopharma innovation policies, regulatory/FDA policies and EPIC Act
S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.